Previous 10 | Next 10 |
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
2024-07-17 10:47:28 ET Summary Monthly article series reports aggregate industry metrics in healthcare. Healthcare providers and life science tools are moderately overvalued, while pharmaceuticals and biotechnology have the worst value and quality scores. Fidelity MSCI Health ...
2024-07-17 10:00:00 ET Summary Bristol-Myers Squibb stock has performed poorly and analysts have started to downgrade its rating citing a 'value trap'. Value traps have all shared a similar set of problems, which don't apply to Bristol-Myers Squibb. The company is facing a ste...
2024-07-13 14:03:47 ET More on Amgen, Biogen, etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Merck: Positive Developments, But Watch The Q2 Earnings Biogen Stock: Cheapish, But With Few Growth Prospects This weight loss stock is the...
2024-07-13 10:10:44 ET More on CureVac BV, GSK, etc. Pfizer Opts To Move Forward With Once-Daily Danuglipron - Don't Hold Your Breath The Next Paxlovid Pfizer: Buy This Big Yielder On The Strong Pipeline Moderna rival CSPC cleared to study RSV shot in China ...
2024-07-13 05:29:00 ET Few pharmaceutical companies are more prominent than Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) . However, their popularity relative to most of their peers hasn't helped them much in the past few years: Both drugmakers have substantially l...
2024-07-12 12:34:04 ET More on Technology Select Sector SPDR ETF: XLK: Low Diversity, Too Concentrated On Nvidia Stock XLK Technology SPDR: You Are Now Taking Unnecessary Risks XLK Is A Solid ETF But SCHG Appears Best In The Bull Run Seeking Alpha's top Quant...
2024-07-12 11:30:02 ET UBS analyst issues NEUTRAL recommendation for PFE on July 12, 2024 10:19AM ET. The previous analyst recommendation was Neutral. PFE was trading at $29.11 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current anal...
2024-07-12 10:50:24 ET Read the full article on Seeking Alpha For further details see: These are the weight loss drug stocks with the most upside - SA Sentiment Survey
2024-07-12 10:27:31 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk once-weekly insulin rejected by FDA ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...